Syncom Formulations (India) Ltd: A Smallcap Pharmaceutical Company Making Waves in the Stock Market
Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has been making headlines in the stock market with its recent performance. On September 10, 2024, the stock hit a 52-week high of Rs. 27.94, outperforming the sector by 3.11% and showing a consecutive gain for the last 5 days. With a remarkable 39.11% increase in returns during this period, the stock is currently trading higher than its moving averages and has shown an impressive 1-year performance of 204.10%, highlighting its strong growth and potential for future gains.
Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has been making waves in the stock market with its recent performance. On September 10, 2024, the company's stock price hit a 52-week high of Rs. 27.94, showcasing its strong growth and potential.
MarketsMOJO, a leading stock market analysis and recommendation platform, has given a 'Buy' call for Syncom Formulations (India) Ltd. This is a testament to the company's positive outlook and potential for future growth.
In terms of price performance, the stock has outperformed the sector by 3.11% and has been on a consecutive gain for the last 5 days, with a remarkable 39.11% increase in returns during this period. The stock also opened with a gain of 2.76% today, further solidifying its strong performance.
The intraday high of Rs. 27.94 (4.37%) and low of Rs. 25.37 (-5.23%) also reflect the volatility and potential for growth in the stock. Additionally, Syncom Formulations (India) Ltd is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.
In comparison to the Sensex, a benchmark index for the Indian stock market, Syncom Formulations (India) Ltd has shown an impressive 1-year performance of 204.10%, while the Sensex has only grown by 22.66%. This further highlights the company's strong performance and potential for future growth.
With its consistent growth and positive outlook, Syncom Formulations (India) Ltd is definitely a stock to watch out for in the pharmaceutical industry. Investors can consider adding this smallcap company to their portfolio for potential long-term gains.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
